Montrusco Bolton Investments Inc. Has $465.62 Million Stock Position in Danaher Co. (NYSE:DHR)

Montrusco Bolton Investments Inc. boosted its stake in shares of Danaher Co. (NYSE:DHR) by 30.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,705,884 shares of the conglomerate’s stock after buying an additional 397,671 shares during the quarter. Danaher makes up 4.9% of Montrusco Bolton Investments Inc.’s portfolio, making the stock its 7th largest position. Montrusco Bolton Investments Inc.’s holdings in Danaher were worth $465,617,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. CarsonAllaria Wealth Management Ltd. bought a new stake in shares of Danaher in the 2nd quarter valued at about $25,000. nVerses Capital LLC bought a new stake in shares of Danaher in the 2nd quarter valued at about $25,000. MidAtlantic Capital Management Inc. bought a new stake in shares of Danaher in the 3rd quarter valued at about $40,000. MFA Wealth Advisors LLC bought a new stake in shares of Danaher in the 2nd quarter valued at about $51,000. Finally, Financial Connections Group Inc. bought a new stake in shares of Danaher in the 2nd quarter valued at about $51,000. Institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 0.3 %

DHR stock opened at $235.83 on Friday. The firm’s fifty day simple moving average is $258.15 and its 200-day simple moving average is $259.88. The company has a market capitalization of $170.34 billion, a P/E ratio of 45.01, a price-to-earnings-growth ratio of 4.32 and a beta of 0.85. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.37 and a quick ratio of 1.01. Danaher Co. has a 12 month low of $215.68 and a 12 month high of $281.70.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 EPS for the quarter, beating the consensus estimate of $1.57 by $0.14. The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. Danaher had a net margin of 16.39% and a return on equity of 10.62%. The business’s revenue for the quarter was up 3.1% on a year-over-year basis. During the same period in the prior year, the firm earned $2.02 EPS. As a group, equities research analysts forecast that Danaher Co. will post 7.5 earnings per share for the current year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, October 25th. Investors of record on Friday, September 27th were issued a dividend of $0.27 per share. This represents a $1.08 dividend on an annualized basis and a yield of 0.46%. The ex-dividend date was Friday, September 27th. Danaher’s dividend payout ratio (DPR) is presently 20.61%.

Analyst Ratings Changes

Several research analysts recently commented on DHR shares. Raymond James reduced their price objective on shares of Danaher from $310.00 to $300.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Barclays reduced their price objective on shares of Danaher from $285.00 to $275.00 and set an “equal weight” rating for the company in a research note on Wednesday, October 23rd. Robert W. Baird reduced their price objective on shares of Danaher from $278.00 to $277.00 and set an “outperform” rating for the company in a research note on Wednesday, October 23rd. Wolfe Research upgraded shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price objective for the company in a research note on Thursday, October 31st. Finally, StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a research note on Monday, November 18th. Six research analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $287.16.

Insider Buying and Selling

In related news, SVP Georgeann Couchara sold 952 shares of the stock in a transaction on Monday, August 26th. The shares were sold at an average price of $268.37, for a total transaction of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares of the company’s stock, valued at approximately $1,130,374.44. This represents a 18.44 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 11.10% of the stock is currently owned by insiders.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.